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We evaluated safety and feasibility of high-pressure transvenous limb perfusion in an upper extremity of
adult patients with muscular dystrophy, after completing a similar study in a lower extremity. A dose
escalation study of single-limb perfusion with 0.9% saline was carried out in nine adults with muscular
dystrophies under intravenous analgesia. Our study demonstrates that it is feasible and definitely safe to
perform high-pressure transvenous perfusion with 0.9% saline up to 35% of limb volume in the upper
extremities of young adults with muscular dystrophy. Perfusion at 40% limb volume is associated with
short-lived physiological changes in peripheral nerves without clinical correlates in one subject. This
study provides the basis for a phase 1/2 clinical trial using pressurized transvenous delivery into upper
limbs of nonambulatory patients with Duchenne muscular dystrophy. Furthermore, our results are ap-
plicable to other conditions such as limb girdle muscular dystrophy as a method for delivering regional
macromolecular therapeutics in high dose to skeletal muscles of the upper extremity.
INTRODUCTION
In human studies of muscular dystrophy, deliv-
ery of therapeutic macromolecules including gene
therapy to skeletal muscles has been limited to
direct intramuscular injection.1–4 Single-limb per-
fusion has been used in delivering gene therapy to
multiple muscles in limbs in preclinical studies.5–8
We have published a dose escalation study of high-
pressure transvenous perfusion with 0.9% saline in
the lower extremities of adult patients with mus-
cular dystrophy to address the safety and feasibil-
ity of this approach in the leg.9 However, for single-
limb gene-based therapy studies of muscular dys-
trophy, the nondominant arm offers advantages
over a leg. Current single-limb delivery methods do
not encompass the proximal muscles of the hip and
shoulder. Walking is the primary function of the
legs and it requires bilateral proximal strength for
meaningful improvement in function. In contrast,
preservation of isolated distal strength and func-
tion sufficient to operate a computer touchpad or an
electric wheelchair in even one hand can have a
major impact on quality of life and can be tested
easily. The smaller muscle mass of the arm also
means that a smaller overall dose will be needed,
reducing both expense and potentially dose-re-
lated systemic toxicity since regional deliveries of
viral vectors also inevitably deliver a systemic
dose.8 Finally, an adverse outcome in which the
muscles in the distal nondominant arm were
damaged would leave the dominant arm func-
tional and not, as in the legs, possibly lead to loss
of ambulation.
Our results obtained in the lower extremities
cannot be assumed to be valid in the upper ex-
tremities since the venous system and muscle
compartments are different. In the upper extrem-
ities the superficial venous system, rather that the
deep system, is dominant, and there are fewer
perforating veins communicating between the
two systems.10,11 The anatomy of the muscle com-
partments and their relation to nerves and blood
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vessels in the forearm are different from the calf.12
Therefore, we undertook a dose escalation safety
study of high-pressure transvenous perfusion with
0.9% saline in the upper extremities of adult pa-
tients with muscular dystrophy.
MATERIALS AND METHODS
Study subjects
Study inclusion criteria were biopsy-confirmed
or mutation-proven Becker muscular dystrophy
(BMD) or other clinically diagnosed muscular dys-
trophies, including limb girdle muscular dystrophy
(LGMD), and ability to give informed consent. Ex-
clusion criteria included positive pregnancy test;
evidence of cardiomyopathy, pulmonary insuffi-
ciency, or renal insufficiency; history of local injury
to upper extremities such as neuropathy, vascular
injury (including arterial or venous thrombosis),
surgery, or trauma; or compartment syndrome.
The study was approved by the Office of Research
Ethics of the University of North Carolina at Chapel
Hill (IRB). Supplementary Material (available on-
line at www.liebertpub.com/hum) includes the po-
tential benefits and risks from consent form.
Written informed consent was obtained from each
subject. This study is registered on ClinicalTrials
.gov with an identifier of NCT00873782.
Pre- and postperfusion studies
Outpatient pre- and postperfusion visits within
1 week of the perfusion included the following:
Doppler ultrasound to assess venous and arterial
damage,13 electrodiagnostic testing using stan-
dard neurographic techniques of four nerves (distal
ulnar, anterior interosseus, posterior interosseus,
and superficial radial nerves) in upper extremities
performed in triplicate by the same examiner,
quantitative muscle testing strength assessments
with a handheld dynamometer (JTechAA104;
JTech Medical, Salt Lake City, UT), and the ac-
tion research arm test (ARAT). The ARAT as-
sesses upper extremity function with four ordinal
subscales: grasp, grip, pinch, and gross move-
ment.14 Preperfusion studies were done bilater-
ally in the upper extremities. Postperfusion
neurography and Doppler studies were only per-
formed in the perfused arm. Also obtained at these
visits were detailed history, neurological exami-
nation, basic metabolic panel (Na + , K + , Cl - , CO2,
BUN, and creatinine), serum creatine kinase
[CK], plasma and urine myoglobin, pregnancy test
for women, and limb photos. Limb segmental
volume (below shoulder) was measured by water
immersion.
Perfusion procedure
The subjects were instructed to take no solid
food after midnight and no liquids after 6 am.
They were admitted to the pediatric intensive care
unit the morning of the perfusion study. An intra-
venous catheter was placed in the peripheral vein
of the control arm for blood draws and intrave-
nous anesthesia (IVA). IVA was administered by
a board-certified anesthesiologist with a combina-
tion of opioids, benzodiazepines, and propofol with
monitoring following the American Society of
Anesthesiology guidelines. Blood pressure, heart
rate, EKG, respiratory rate, and pulse oximetry
were continuously monitored. A Somanetics INVOS
near-infrared oxygen monitor sensor (Somanetics
Corporation, Troy, MI) was placed on each forearm
to monitor distal limb tissue oxygenation,15 while a
second pulse oximetry was placed onto the finger of
the perfused limb.
Basic metabolic panel, CK, urine, and serum
myoglobin were checked at baseline (immediately
preperfusion) and hourly postperfusion until the
patient was deemed ready for discharge. A portable
transthoracic echocardiograph (Sonos 5500; Philips
Healthcare, Andover, MA) was used to assess car-
diac systolic function and measure systolic and di-
astolic dimensions. In addition, we continuously
observed for microcavitation in the right atrium
during infusion that would indicate saline leak be-
cause of loss of cuff occlusion. An upper extremity
was chosen for the study for each subject (the non-
dominant hand unless the subject requested other-
wise). An intravenous catheter (1.5 inches long and
18 or 20 gauge) was placed percutaneously in a pe-
ripheral vein in dorsum of the hand. Using the
segmental limb volume premeasured by water dis-
placement and the protocol-specified perfusion dose,
the volume of normal 0.9% saline to be infused as a
percent of the segmental limb volume was deter-
mined. A pneumatic tourniquet (ATS 2000; Zimmer,
Warsaw, IN) was placed below the shoulder at the
line marked during limb volume measurements at
the preperfusion visit. The inflation pressure was
set to 310–325 mm Hg and tested briefly while the
subject was awake. This is the pressure re-
commended for intravenous regional anesthesia.16
Saline was infused with a dual-pump system
that consisted of an FMS 2000 Rapid Infuser
(Belmont Instrument Corporation, Billerica, MA)
and a Medfusion 3500 syringe pump, both of which
are approved for clinical use (Medex Inc., Carlsbad,
CA) (Fig. 1).17 We modified our lower extremity
perfusion protocol to add the syringe pump down-
stream from the Belmont pump. We did so after
infusion of adeno-associated virus vector serotype 8
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(AAV8)-CMV-GFP vector at the standard dose of
1 · 1013 v.g./kg body weight in a canine limb per-
fusion experiment using the Belmont system alone
failed to produce detectable green fluorescent pro-
tein expression. We suspected that the internal
aluminum heating plates, which have very large
surface areas, were adsorbing and/or inactivating
the AAV viral vectors. This new dual-pump system
has successfully been tested in the canine DMD
model with reproducible efficacy of gene transfer
identical to the original animal studies using the
Harvard pump, which is not approved for human
subject.18 The infusion rate was set at 80 ml/min for
the Belmont pump. The Belmont FMS 2000 Rapid
Infuser will infuse to a maximum line pressure of
300 mm Hg. When a line pressure of 300 mm Hg
is reached, the infusion rate is automatically de-
creased. The syringe pump was set to infuse 20 ml
of saline at a rate of 5 ml/min delivered in the initial
4–5 min of the perfusion simultaneously with Bel-
mont pump. Following completion of the infusion,
the tourniquet remained inflated for 1 min and was
then deflated. Photos of the limb were taken before,
during, and after perfusion.
We measured compartmental pressures in the
dorsal and volar compartments in the forearm of
the perfused limb in all subjects during the perfu-
sion and immediately after the tourniquet was
released. We employed continuous monitoring by
indwelling catheters (Indwelling Slit Catheter;
Stryker Surgical, Kalamazoo, MI) before, during,
and after the perfusion until the pressures re-
turned to less than 35 mm Hg.
Magnetic resonance imaging acquisition
and data analysis
Seven subjects (10–16) had magnetic resonance
imaging (MRI) studies preperfusion at baseline
and immediately postperfusion. It was technically
challenging to position both arms in the scanner in
a position that was comfortable for the subjects.
The arms were either positioned straight on the
abdomen over a plastic frame or crossed over on the
chest/abdomen on a plastic frame, in order for both
forearms to be imaged. T2 fat-saturated (FS) im-
ages were obtained using the same protocols as our
prior study,9 and then manually segmented into
several groups of muscles using open source soft-
ware ITK-SNAP 2.0.19,20 The pre- and postperfu-
sion images were aligned using the ulna as a
landmark. Volumetric data and T2FS intensity
data were obtained after the segmentation was
finalized.
Dose escalation
The initial study was performed with an infusion
volume of 5% limb volume. Infusion volume was
then increased in a stepwise fashion with approval
of the independent safety monitor (Table 1).
Safety boundaries
Safety boundaries were set conservatively in
anticipation that these changes may not be clini-
cally significant but may predict problems at
the next higher dose. The safety boundaries for
limb tissue oximetry ( < 31%) and compartment
pressures ( > 35 mm Hg) were based on a study of
chronic exertional compartment syndrome with
transient pain during exercise without muscle
damage.15 For electrodiagnostic nerve testing, the
postperfusion versus preperfusion changes were
set to > 1 msec for the distal motor latency, < 75% of
compound muscle action potential (CMAP) or sen-
sory nerve action potential (SNAP) amplitude and
velocity. Cardiac function and dimensions were to
remain within 90% of baseline. Quantitative mus-
cle testing and timed walking were set to be within
85% baseline. Venous Doppler was used to evaluate
for venous stenosis/thrombosis and arterial Dopp-
Figure 1. Dual-pump infusion system. Color images available online at
www.liebertpub.com/hum
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ler to detect stenosis. For laboratory values, we set
criteria for serum creatinine of > 0.5 mg/dl over
baseline, and for serum potassium of > 0.5 mM over
baseline or > 5.0 mM. We did not specify the safety
boundary for CK, urine, and serum myoglobin, as
ascribing clinical significance to specific values
with high baseline values and underlying muscle
disease is problematic because of high variability.21
Safety monitoring
A local independent safety monitor reviewed the
safety report prepared after the completion of each
subject’s study and approved the infusion param-
eters for the next subject.
An external independent safety officer was ap-
pointed by National Institute of Arthritis and
Musculoskeletal and Skin Diseases. Biannual safe-
ty reports were submitted via KAI Research, Inc.
(KAI Research, Inc., Rockville, MD).
RESULTS
Subjects
Nine subjects, aged 23–50 years, were studied.
Seven were male and two were female. One had
BMD, one had limb LGMD 2A, three had LGMD
2B, two had LGMD 2E, and two had LGMD of
unknown subtype. One subject (08) was studied
before our implementation of the dual-pump sys-
tem (see Materials and Methods section). All other
subjects were studied with the dual-pump system.
The perfusion procedure
Perfusion. The initial study was performed
with an infusion volume of 5% limb volume. In-
fusion volume was then increased in a stepwise
fashion per protocol. Because of abnormalities in
nerve conduction studies (NCS) observed at 40%
limb volume infusion in subject 15, infusion volume
was decreased to 35% for subject 16. Table 1 details
the specific perfusion parameters. Average infu-
sion rate varied with the size of the perfusion
catheter placed. The average rate was 75 ml/min in
5 subjects with 18-gauge catheters and 48 ml/min
in 4 subjects with 20-gauge catheters. All subjects
had visible limb volume expansion, firmness to
touch, and enlargement of forearm circumference.
Four (12, 13, 15, and 16) developed painless pete-
chiae under the tourniquet. There was no cardiac
dysfunction or signs of systemic fluid overload as
measured by echocardiogram, EKG, heart rate,
respiratory rate, or cutaneous oxygen saturation
(Supplementary Table S1). None of the nine re-
ported discomfort or remembered the perfusion
procedure after recovering from anesthesia (*10–
15 min postperfusion). Some subjects commented
that they felt that the perfused arm was ‘‘tight’’ up
to 1–2 hr postperfusion.
Subject 10 was a 27-year-old woman who was
the only participant who had been treated with
long-term corticosteroids (*17 years). She had
noticeably small veins and thin skin on her hand/
forearm by visual inspection. The line pressure of
300 mm Hg (which causes the Belmont infuser to
automatically adjust the perfusion rate down) was
reached often during her study, and as a conse-
quence she had one of the lowest average perfusion
rates (42 ml/min). Other parameters of her study
were not different from the remaining subjects.
Subject 14, who received 43% rather than 35% ra-
ther limb perfusion because of calculation error,
had more prolonged recovery of his limb size to
baseline, but no other issues.
Compartment pressure and tissue oxygen satu-
ration monitoring. In all subjects, postperfusion
compartment pressure returned to below the safety
cutoff of 35 mm Hg within 15 min and postperfu-


































08 5 2.7 136 0 18 2 80 10/23 0
09 10 2.2 200 20 18 3 80 98/34 0
10 20 2.2 420 20 20 10 42 15/12 + 2.5
11 20 3.1 601 20 18 8 75 59/112 + 2.0
12 25 2.3 555 20 18 8 69 —/71 + 1.7
13 30 2.7 798 20 18 11 73 82/104 + 3.0
14 43a 2.4 1024 20 20 18 57 43/13 + 3.0
15 40 2.6 921 20 20 16 58 142/30 + 2.5
16 35 1.7 575 20 20 16 36 108/134 + 4.5
aThis subject was intended to have 35% perfusion volume.
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sion tissue oxygen saturation returned to baseline
or above baseline within 5 min. The highest peak
compartment pressure was 142 mm Hg in subject
15 with 40% perfusion volume (Table 1).
Pre- and postperfusion studies
Clinical assessment. None of the postperfusion
assessments showed any evidence of injury re-
lated to perfusion except for the NCS (detailed
results below). All subjects had returned to sub-
jective baseline except for healing needle punc-
ture sites at the postperfusion visit. All subjects
had a telephone follow-up within 2 weeks of post-
perfusion and none reported problems in the per-
fused arm. Petechiae typically resolved completely
by 2–3 weeks per phone follow-up. No serious ad-
verse events occurred during this study.
Laboratory studies. None had abnormal levels
of renal function (creatinine) or potassium. The
range of fluctuation in CK was consistent with
normal variation described in muscular dystro-
phies attributed to normal activity (Supplemen-
tary Table S1).21,22
Venous and arterial Doppler study. All subjects
had normal venous and arterial studies pre- and
postperfusion (Supplementary Table S1).
Quantitative muscle strength test and functional
arm test: action research arm test. Table 2 sum-
marizes the quantitative muscle strength test
data postperfusion compared with preperfusion.
Large variations, similar in perfused and control
arms, were observed as have been previously re-
ported.23 There were no decreases in postperfusion
arm/hand function measured by ARAT (Supple-
mentary Table S1).
Electrophysiology studies. All except subject
15 had unchanged postperfusion NCS. Subject 15
had abnormal postperfusion studies at 3 days post-
perfusion in which the amplitude of the distal CMAP
in all three nerves tested exceeded the prespecified
safety boundary of more than a 25% reduction (Ta-
ble 3), while all other parameters, including distal
motor latencies and conduction velocities, remained
unchanged compared with baseline (Supplementary
Table S1). The postperfusion NCS were repeated
twice. At 25 days postperfusion, only the amplitude
of the distal CMAP of the anterior interosseous
nerve exceeded the 25% reduction boundary and
this returned to baseline at 5 weeks postperfusion
(Table 3). At no time were there symptoms or
clinical neurological deficits associated with the
abnormal electrophysiological findings.
MRI studies. Seven subjects (10–16) had MRI
studies. Three studies (10, 12, and 13) were ex-
Table 2. Changes in quantitative muscle strength testing
(postperfusion compared with baseline)
Subject Perfused arm Control arm
08 - 9% to + 25% - 3% to + 53%
09 - 20% to + 50% - 14.7% to + 32%
10 0 to + 90% - 14.7% to + 33%
11 - 43% to + 54% - 29.8% to + 50%
12 - 11% to + 64% - 27% to + 35%
13 - 24% to + 10% - 12.5% to + 6.5%
14 0 to + 42% - 20% to + 6%
15 - 75% to + 94% - 75% to + 39%
16 - 2% to + 8% - 32% to + 28%
The symbol ‘‘ - ’’ denotes strength reduction and ‘‘ + ’’ denotes strength
increase in postperfusion test compared with preperfusion baseline.
Quantitative muscle strength was measured in pounds (lb).
























Trial 1 1.50 1.20 — 0.90 — 1.60 —
Trial 2 1.90 1.20 — 1.00 — 1.60 —
Trial 3 1.60 1.20 — 1.20 — 1.60 —




Trial 1 1.5 1.3 — 1.3 — — —
Trial 2 2.1 1.3 — 2.3 — — —
Trial 3 2.5 1.2 — 3.2 — — —
Mean 2.0 1.3 - 35% 2.3 + 15%
Ulnar nerve Trial 1 13.7 9.0 — 13.2 — — —
Trial 2 13.9 9.6 — 12.5 — — —
Trial 3 12.4 9.5 — 12.7 — — —
Mean 13.3 9.4 - 29% 12.8 - 4% — —
aPoststudy 1 was performed 3 days postperfusion, poststudy 2 was performed 25 days postperfusion, and poststudy 3 was performed 5 weeks postperfusion.
Values in bold indicate values that exceeded the prespecified safety boundary of more than a 25% reduction.
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cluded from analysis because of marked artifacts
and low image quality. For subjects 11, 13, 15, and
16, the T2 fat saturation (T2FS) sequences were
started at 55, 41, 63, and 43 min postperfusion.
Postperfusion MRI showed increases in volume of
the volar and dorsal compartments (Fig. 2). Com-
partmental volume increases ranged from 13% to
43% for the 30–40% limb volume perfusion studies
in subjects (patients 13, 15, and 16) and were larger
in the volar compartment (Fig. 3).
DISCUSSION
Our study demonstrates that it is feasible and
definitely safe to perform high-pressure transve-
nous perfusion with 0.9% saline up to 35% of limb
volume in the upper extremities of young adults
with muscular dystrophy. Perfusion at 40% limb
volume was associated with short-lived physiolog-
ical changes in peripheral nerves without clinical
correlates in one subject. With the infusion pa-
rameters used, there was no detectable regional
injury to the arteries, veins, or muscles in the limb,
nor was there systemic cardiac or renal toxicity
observed in any subject. Subjects recovered within
4 hr and were discharged home. Furthermore, a
phone follow-up in 2 weeks revealed no self-
reported concerns of the subjects. In contrast to
arterial limb perfusion methods, no surgical pro-
cedure such as femoral artery catheterization or
cut-down was necessary.24
The clinical significance of the transiently re-
duced amplitudes of 28–38% in CMAP is unclear.
It is unlikely due to an acute nerve injury such as
neurapraxia, as conduction velocities were normal
rather than slowed as they would be with this
condition. Axonal injury was considered but the
relatively rapid resolution of the reduced CMAP
amplitudes and the absence of significant dener-
vation on needle EMG refutes this. One possibility
is that the reduction of amplitude was because
of fluid entering the muscle and dampening the
evoked response similar to electroporation re-
ported by Collins et al.25 The time course of ab-
normality is not typical of that seen in ischemic
injury to the nerve.26 Given that the conduction
velocities and distal latencies of the same nerves in
this subject were unchanged postperfusion, and
that there was no evidence for nerve/muscle im-
pairment by history or clinical evaluation, we
concluded that these electrophysiologic abnormal-
ities were not of clinical significance.
Figure 3. Postperfusion versus preperfusion muscle volume changes
in percent by compartments. Color images available online at www
.liebertpub.com/hum
Figure 2. Axial view of preperfusion and postperfusion at the level of proximal two-thirds in the forearm. Increased intensity areas in these T2 fat saturation
images indicate increased fluid.
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This study used lower cuff pressures than in
nonhuman primate studies (310–325 mm Hg vs.
450–700 mm Hg in nonhuman primates).5,27 The
maximum perfusion volumes of 30–40% in this up-
per extremity study were higher than the maximum
of 20% in our lower extremity study.9 This 30–40%
volume was similar to that used for whole pelvic
limb perfusion in dogs with the AAV-mini-dystro-
phin construct that has produced robust mini-dys-
trophin expression.28 Peak tissue/compartment
pressures of 142 mm Hg during the perfusion were
comparable to the peak pressures of 155 mm Hg in
our lower extremity study9 and 175 mm Hg in
studies of nonhuman primates.5 The largest volume
infused (*1 liter) was delivered in less than 18 min,
a time frame that is well within the established
safety time limit of 1.5–2 hr of tourniquet time for
regional intravenous limb anesthesia.29
The rate of infusion used in this study was up to
80 ml/min, which is comparable to that used in
some large animal studies of 60–120 ml/min.28,30,31
Based on experience from preclinical canine ther-
apeutic trials, we adopted a dual-pump system.18
With this system, the syringe pump can be used to
deliver the therapeutic agent (such as a viral vec-
tor) bypassing the Belmont infuser, while the
needed volume and pressure are delivered by the
Belmont infuser (Fig. 1). The patients in this study
consisted of LGMD and BMD. The only patient in
this study who had been on long-term corticoste-
roid use (*17 years) was subject 10 with LGMD
2E. She was Cushingoid with a BMI of 27. She also
had the lowest average perfusion rate of 42 ml/min.
Long-term use of steroids may cause smaller and
more fragile vasculatures, including superficial
venous structures, and we did not observe any ad-
verse effects with the high pressures that we em-
ployed. The vasculature of DMD patients with
long-term use of corticosteroid may be different
and perfusion rates lower than in this study may be
effective. Perfusion rates of 10 or 35 ml/min have
been used in dogs to successfully deliver gene
therapy.7 However, lower perfusion rates mean
longer perfusion and anesthesia time. Additional
studies are needed to address these questions.
A recent safety, dose escalation, and efficacy
study in golden retriever muscular dystrophy used
high-pressure transvenous perfusion of the fore-
limb to deliver recombinant AAV8 carrying a
modified U7snRNA sequence promoting exon
skipping to restore a functional in-frame dystro-
phin transcript. Improvement in muscle strength
was most consistently achieved with a dose of
5 · 1013 vg/kg infused at 7–20 mL/min with peak
infusion pressures of 150 and 380 mm Hg at 20%
and 40% of the forelimb volume, respectively.7 Our
study has demonstrated that these same infusion
parameters can be easily implemented and safely
employed in patients with muscular dystrophy.
These two studies provide the basis for a phase 1/2
clinical trial using high-pressure transvenous de-
livery into upper limbs of patients with Duchenne
muscular dystrophy. Furthermore, our results are
applicable to conditions other than muscular dys-
trophy as a method for delivering regional macro-
molecular therapeutics in high dose to skeletal
muscles of the upper extremity.
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